Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
How would you sequence therapy for patient with metastatic RCC who was not able to tolerate TKI but now have progress on single agent IO?
Would you re-challenge TKI or try a different TKI?
Related Questions
Would you offer neoadjuvant chemotherapy to high grade T1 urothelial carcinoma in a bladder diverticulum?
How would you incorporate results from the PRESTO trial into your practice in light of greater use of PSMA PET scans for prostate cancer?
In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
When recommending salvage RT post-prostatectomy for an ultra-sensitive PSA level <0.1, do you still recommend concurrent hormonal therapy?
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?
What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
Would you use fezolinetant for hot flashes for men on ADT?